中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 6
Jun.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(6): 1156-1161

Association between serum endothelial cell-specific molecule 1 and cirrhotic cardiomyopathy

DOI: 10.12449/JCH240614

  • Third Department of Liver Disease Center，Beijing YouAn Hospital，Capital Medical University，Beijing 100069，China

Research funding:

Beijing Municipal Administration of Hospitals Incubating Program (PX2024061)

More Information
  • Corresponding author: ZHANG Jing， drzhangjing@163.com （ORCID： 0000-0002-3082-8330）
  • Received Date: 2023-12-26
  • Accepted Date: 2024-02-08
  • Published Date: 2024-06-25
    Abstract
  •   Objective  Cirrhotic cardiomyopathy （CCM） refers to cardiac dysfunction and electrophysiological disorder caused by liver cirrhosis and is closely associated with the prognosis of patients with liver cirrhosis. Endothelial cell-specific molecule 1 （endocan） can be used as a diagnostic marker for cardiovascular diseases， and it remains unclear whether it is involved in the pathogenesis of CCM. The aim of this study is to investigate the expression of serum endocan in patients with CCM and its possible role in the development of CCM.  Methods  This cross-sectional study was conducted among the patients with liver cirrhosis who were consecutively admitted to Beijing YouAn Hospital， Capital Medical University， from January 2019 to January 2021， and according to the presence or absence of CCM， the patients were divided into CCM group with 19 patients and non-CCM group with 106 patients. ELISA was used to measure the serum level of endocan， and its correlation with liver function and cardiac function was analyzed. The independent-samples t test was used for comparison of normally distributed continuous data between two groups， and the Mann-Whitney U rank sum test was used for comparison of continuous data with skewed distribution between two groups； the chi-square test was used for comparison of categorical data between groups. A Pearson or Spearman correlation analysis was used to investigate the correlation between indicators， and the receiver operating characteristic （ROC） curve was used to assess the CCM predictive model.  Results  The CCM group had a significantly higher expression level of serum Endocan than the non-CCM group （2.69±0.43 ng/mL vs 2.23±0.52 ng/mL， t=2.247， P=0.034）. The patients with compensated cirrhosis had a significantly lower expression level of serum endocan than those with decompensated cirrhosis （2.41±0.37 ng/mL vs 2.72±0.49 ng/mL， t=3.214， P=0.02）. In the CCM group， the serum level of endocan was positively correlated with Child-Pugh score （r=0.509， P=0.026） and MELD-Na score （r=0.484， P=0.036） and was negatively correlated with mean arterial pressure （r=-0.591， P=0.013） and mitral ratio of peak early to late diastolic filling velocity （r=-0.515， P=0.042）. The serum endocan had an area under the ROC curve of 0.658 （95%CI： 0.522～0.781） in predicting CCM， when the cut-off value was 2.61 ng/mL， the sensitivity was 67.1% and the specificity was 73.7%.  Conclusion  There is a certain association between serum endocan and CCM， and serum endocan may be involved in the pathogenesis of CCM.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    LIU HQ, NGUYEN HH, YOON KT, et al. Pathogenic mechanisms underlying cirrhotic cardiomyopathy[J]. Front Netw Physiol, 2022, 2: 849253. DOI: 10.3389/fnetp.2022.849253.
    [2]
    WANG WW, LI HY, WANG ZC, et al. Progress in the application of ultrasonic cardiogram in cirrhotic cardiomyopathy[J]. Clin J Med Offic, 2022, 50( 9): 900- 903. DOI: 10.16680/j.1671-3826.2022.09.07.

    王微微, 李宏宇, 王忠超, 等. 超声心动图在肝硬化心肌病中应用进展[J]. 临床军医杂志, 2022, 50( 9): 900- 903. DOI: 10.16680/j.1671-3826.2022.09.07.
    [3]
    MØLLER S, LEE SS. Cirrhotic cardiomyopathy[J]. J Hepatol, 2018, 69( 4): 958- 960. DOI: 10.1016/j. jhep.2018.01.006.
    [4]
    MØLLER S, DANIELSEN KV, WIESE S, et al. An update on cirrhotic cardiomyopathy[J]. Expert Rev Gastroenterol Hepatol, 2019, 13( 5): 497- 505. DOI: 10.1080/17474124.2019.1587293.
    [5]
    LIANG SY, LIN Q, SONG JL, et al. Role of bile acids in cirrhosis-related cardiomyopathy[J]. J Clin Hepatol, 2022, 38( 10): 2383- 2386. DOI: 10.3969/j.issn.1001-5256.2022.10.035.

    梁世洋, 林强, 宋俊良, 等. 胆汁酸在肝硬化心肌病中的作用[J]. 临床肝胆病杂志, 2022, 38( 10): 2383- 2386. DOI: 10.3969/j.issn.1001-5256.2022.10.035.
    [6]
    KIM JS, KO GJ, KIM YG, et al. Plasma endocan as a predictor of cardiovascular event in patients with end-stage renal disease on hemodialysis[J]. J Clin Med, 2020, 9( 12): 4086. DOI: 10.3390/jcm9124086.
    [7]
    TOSHIKUNI N, OZAKI K, GEORGE J, et al. Serum endocan as a survival predictor for patients with liver cirrhosis[J]. Can J Gastroenterol Hepatol, 2015, 29( 8): 427- 430. DOI: 10.1155/2015/153805.
    [8]
    BALTA S, BALTA I, MIKHAILIDIS DP. Endocan: A new marker of endothelial function[J]. Curr Opin Cardiol, 2021, 36( 4): 462- 468. DOI: 10.1097/HCO.0000000000000867.
    [9]
    CELIK ZE, DEMIR F, YONAR H, et al. Association of endocan expression with clinicopathological prognostic parameters in breast carcinoma[J]. Cancer Biomark, 2021, 32( 4): 471- 477. DOI: 10.3233/CBM-201026.
    [10]
    KECHAGIA M, PAPASSOTIRIOU I, GOURGOULIANIS KI. Endocan and the respiratory system: A review[J]. Int J Chron Obstruct Pulmon Dis, 2016, 11: 3179- 3187. DOI: 10.2147/COPD.S118692.
    [11]
    SENOCAK GNC, YAPCA OE, YILMAZ EPT, et al. May endocan be a new biomarker in the diagnosis of endometriosis?[J]. J Gynecol Obstet Hum Reprod, 2022, 51( 7): 102423. DOI: 10.1016/j.jogoh.2022.102423.
    [12]
    OKYAY K. Cardiac biomarkers in coronary slow flow: Endocan and omentin-1[J]. Turk Kardiyol Dern Ars, 2019, 47( 4): 249- 250. DOI: 10.5543/tkda.2019.14701.
    [13]
    BEHNOUSH AH, KHALAJI A, BAHIRAIE P, et al. Endocan as a marker of endothelial dysfunction in hypertension: A systematic review and meta-analysis[J]. Hypertens Res, 2023, 46( 10): 2388- 2399. DOI: 10.1038/s41440-023-01402-y.
    [14]
    DELEHEDDE M, DEVENYNS L, MAURAGE CA, et al. Endocan in cancers: A lesson from a circulating dermatan sulfate proteoglycan[J]. Int J Cell Biol, 2013, 2013: 705027. DOI: 10.1155/2013/705027.
    [15]
    ZUWALA-JAGIELLO J, PAZGAN-SIMON M, SIMON K, et al. Serum endocan level in diabetes mellitus of patients with cirrhosis and risk of subsequent development of spontaneous bacterial peritonitis[J]. J Physiol Pharmacol, 2019, 70( 3): 10.26402/jpp.2019.3.06. DOI: 10.26402/jpp.2019.3.06.
    [16]
    HEN J, JIANG L, YU X, et al. Endocan: a key player of cardiovascular disease[J]. Front Cardiovasc Med, 2022, 8. DOI: 10.3389/fcvm.2021.798699.
    [17]
    BALTA S, MIKHAILIDIS DP, DEMIRKOL S, et al. Endocan: A novel inflammatory indicator in cardiovascular disease?[J]. Atherosclerosis, 2015, 243( 1): 339- 343. DOI: 10.1016/j.atherosclerosis.2015.09.030.
    [18]
    HIROOKA Y. How can endocan be used as a specific biomarker of endothelial dysfunction in hypertension?[J]. Hypertens Res, 2024, 47( 3): 794- 795. DOI: 10.1038/s41440-023-01542-1.
    [19]
    HSU SJ, LIN TY, WANG SS, et al. Endothelin receptor blockers reduce shunting and angiogenesis in cirrhotic rats[J]. Eur J Clin Invest, 2016, 46( 6): 572- 580. DOI: 10.1111/eci.12636.
    [20]
    KLISIĆ A, KAVARIĆ N, ABENAVOLI L, et al. Is endocan a novel potential biomarker of liver steatosis and fibrosis?[J]. J Med Biochem, 2020, 39( 3): 363- 371. DOI: 10.2478/jomb-2019-0042.
    [21]
    YANG JH, SHENG SH, YANG QW, et al. Endocan silencing induces programmed cell death in hepatocarcinoma[J]. Oncol Lett, 2017, 14( 5): 5333- 5339. DOI: 10.3892/ol.2017.6857.
    [22]
    HUANG X, CHEN C, WANG X, et al. Prognostic value of endocan expression in cancers: Evidence from meta-analysis[J]. Onco Targets Ther, 2016, 9: 6297- 6304. DOI: 10.2147/OTT.S110295.
    [23]
    SCHWABL P, BUCSICS T, SOUCEK K, et al. Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites[J]. Liver Int, 2015, 35( 9): 2121- 2128. DOI: 10.1111/liv.12795.
    [24]
    JR WTF. Endocan in hypertension and cardiovascular disease[J]. Angiology, 2014, 65( 9): 757- 759. DOI: 10.1177/0003319713514478.
    [25]
    VOIOSU AM, BĂLĂNESCU P, DAHA I, et al. The diagnostic and prognostic value of serum endocan in patients with cirrhotic cardiomyopathy[J]. Rom J Intern Med, 2018, 56( 3): 182- 192. DOI: 10.2478/rjim-2018-0007.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (192) PDF downloads(24) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return